RT Journal Article
SR Electronic
T1 Early introductions and community transmission of SARS-CoV-2 variant B.1.1.7 in the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.10.21251540
DO 10.1101/2021.02.10.21251540
A1 Tara Alpert
A1 Erica Lasek-Nesselquist
A1 Anderson F. Brito
A1 Andrew L. Valesano
A1 Jessica Rothman
A1 Matthew J. MacKay
A1 Mary E. Petrone
A1 Mallery I. Breban
A1 Anne E. Watkins
A1 Chantal B.F. Vogels
A1 Alexis Russell
A1 John P. Kelly
A1 Matthew Shudt
A1 Jonathan Plitnick
A1 Erasmus Schneider
A1 William J. Fitzsimmons
A1 Gaurav Khullar
A1 Jessica Metti
A1 Joel T. Dudley
A1 Megan Nash
A1 Jianhui Wang
A1 Chen Liu
A1 Pei Hui
A1 Anthony Muyombwe
A1 Randy Downing
A1 Jafar Razeq
A1 Stephen M. Bart
A1 Steven Murphy
A1 Caleb Neal
A1 Eva Laszlo
A1 Marie L. Landry
A1 Peter W. Cook
A1 Joseph R. Fauver
A1 Christopher E. Mason
A1 Adam S. Lauring
A1 Kirsten St. George
A1 Duncan R. MacCannell
A1 Nathan D. Grubaugh
YR 2021
UL http://medrxiv.org/content/early/2021/02/12/2021.02.10.21251540.abstract
AB The emergence and spread of SARS-CoV-2 lineage B.1.1.7, first detected in the United Kingdom, has become a national public health concern in the United States because of its increased transmissibility. Over 500 COVID-19 cases associated with this variant have been detected since December 2020, but its local establishment and pathways of spread are relatively unknown. Using travel, genomic, and diagnostic testing data, we highlight the primary ports of entry for B.1.1.7 in the US and locations of possible underreporting of B.1.1.7 cases. New York, which receives the most international travel from the UK, is likely one of the key hubs for introductions and domestic spread. Finally, we provide evidence for increased community transmission in several states. Thus, genomic surveillance for B.1.1.7 and other variants urgently needs to be enhanced to better inform the public health response.Competing Interest StatementM.J.M, G.K., J.M., J.T.D., M.N., and C.E.M. work for Tempus Labs. K.S.G. receives research support from ThermoFisher for the development of assays for the detection and characterization of viruses. All other authors declare no competing interests.Funding StatementWe thank A. Grills and S. Morrison from the Centers for Disease Control and Prevention (CDC) for providing the OAG flight data, all of the frontline and essential workers for their continued service during the pandemic, and our friends and family - particularly V. Parsons, P. Jack, and S. Taylor - for their support. This work was funded by CTSA Grant Number TL1 TR001864 (T.A. and M.E.P.), Fast Grant from Emergent Ventures at the Mercatus Center at George Mason University (N.D.G.), CDC Contract # 75D30120C09570 (N.D.G.), CDC Contract # 75D30120C09870 (A.S.L.). Initial funding for sequencing at the Wadsworth Center was provided by the New York Community Trust. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board from the Yale University Human Research Protection Program determined that the RT-qPCR testing and sequencing of de-identified remnant COVID-19 clinical samples obtained from clinical partners conducted in this study is not research involving human subjects (IRB Protocol ID: 2000028599). Residual nasopharyngeal and saliva specimens from individuals who tested positive for SARS-CoV-2 by RT-PCR were obtained from the Michigan Medicine Clinical Microbiology Laboratory, University (of Michigan) Health Services, and LynxDx (Ann Arbor, MI). This work was approved by the University of Michigan Institutional Review Board (IRB Protocol ID: HUM185966), Expanded sequencing in January 2020 was performed as part of a public health investigation. Residual portions of respiratory specimens from individuals who tested positive for SARS-CoV-2 by RT-PCR were obtained from the Wadsworth Center and partnering clinical laboratories. This work was approved by the New York State Department of Health Institutional Review Board, under study numbers 02-054 and 07-022. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used to produce all of the figures are included in Data S1 and Data S2. Genomic data are available on GISAID (see Data S2 for accession numbers). The air passenger data used in this study are proprietary and were purchased from OAG Aviation Worldwide Ltd. These data were used under the United States Centers for Disease Control and Prevention license for the current study and so are not publicly available. The authors are available to share the air passenger data upon reasonable request and with the permission of OAG Aviation Worldwide Ltd.